Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus

Clinical Rheumatology

Volumn 26, Issue 4, 2007, Pages 582-583

  Matsukawa, Yoshihiro ^a   Igei, Kohmei ^a   Nozaki, Takamasa ^a   Ohki, Takafumi ^a   Shimizu, Takako ^a   Kitamura, Noboru ^a   Mitamura, Ko ^a   Takei, Masami ^a   Kasamaki, Yuji ^a   Sawada, Shigemasa ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epoprostenol; Pulmonary hypertension; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; BERAPROST; DNA ANTIBODY; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PROSTACYCLIN; SM ANTIBODY;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HUMAN; JAPAN; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33847662492     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0170-5     Document Type: Article

References (10)

1. Sulica R, Poon M (2004) Current medical treatment of pulmonary arterial hypertension. Mt Sinai J Med 71:103-114
2. Robbins IM, Gaine SP, Schilz R et al (2000) Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 117:14-18
3. Horn EM, Barst RJ Poon M (2000) Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 118:1229-1230
4. Kongo KO, Badsha H, Thumboo J et al (2003) Intermittent epoprostenol infusions in systemic lupus erythematosus associated pulmonary hypertension - A series of three cases. Ann Acad Med Singapore 32:118-121
5. Ooiwa H, Miyazawa T, Yamanishi Y et al (2000) Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue. Intern Med 39:320-323
6. Scorza R, Caronni M, Mascagni B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503-508
7. Matsukawa Y, Saito O, Aoki M et al (2002) Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins Leukot Essent Fatty Acids 67:45-49
8. Kyotani S (2004) Problems and prospects of continuous intravenous prostacyclin therapy for pulmonary hypertension due to collagen disease. Rheumatology (Tokyo) 31:535-541 (In Japanese)
9. Yokoo N, Waki K, Aragaki Y et al (2004) Intravenous administration of Frolan. Progress in Medicine 24:286-289 (In Japanese)
10. Melian EB, Goa KL (2002) Beraprost: A review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 62:107-133